Loading…
Clene Inc. is projected to rise to $11.94 by 2027, a +79% move from its current price of $6.69. CLNN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $6.34 | $6.69 | $7.06 | +0.05% |
| May 30 | $6.21 | $6.70 | $7.23 | +0.10% |
| May 31 | $6.10 | $6.70 | $7.35 | +0.15% |
| Jun 1 | $6.02 | $6.70 | $7.46 | +0.20% |
| Jun 2 | $5.95 | $6.71 | $7.56 | +0.25% |
| Jun 3 | $5.88 | $6.71 | $7.65 | +0.30% |
| Jun 4 | $5.82 | $6.71 | $7.74 | +0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.82 | $6.71 | $7.74 | +0.35% |
| Week 2 | $5.51 | $6.74 | $8.24 | +0.70% |
| Week 3 | $5.28 | $6.76 | $8.65 | +1.05% |
| Week 4 | $5.10 | $6.78 | $9.02 | +1.40% |
| Week 5 | $4.95 | $6.81 | $9.36 | +1.76% |
| Week 6 | $4.82 | $6.83 | $9.68 | +2.11% |
| Week 7 | $4.71 | $6.85 | $9.99 | +2.47% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Clene Inc. is a clinical-stage pharmaceutical company that focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The lead drug candidate CNM-Au8 is being studied in various Phase 2 trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc.
is headquartered in Salt Lake City, Utah.
Clene Inc. (CLNN) operates in the Consumer Defensive sector. The current price is $6.70 and the market capitalization stands at $85.61M, with an overall market rank of 4322. The near-term outlook is framed by a 30-day technical picture that includes a bullish sentiment signal.
A major floor 41.4% below — a decisive break under it would weaken the trend.
The nearest floor, 13.3% below — buyers have tended to step in here.
The nearest ceiling, 20.9% above — a clean break opens room to run.
A major ceiling 36.8% above — clearing it would confirm fresh momentum.
Key CLNN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CLNN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.73 | Sell | $6.69 | Sell |
| MA 10 | $6.75 | Sell | $6.72 | Sell |
| MA 20 | $6.76 | Sell | $6.66 | Buy |
| MA 50 | $6.24 | Buy | $6.33 | Buy |
| MA 100 | $5.63 | Buy | $6.15 | Buy |
| MA 200 | $6.48 | Buy | $6.01 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.45 | Neutral |
| Stoch RSI (14) | 24.80 | Neutral |
| CCI (20) | -11.66 | Neutral |
| Williams %R (14) | -69.31 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | -8.10 | Sell |
| Bollinger %B (20,2) | 0.47 | Neutral |
| Stochastic %K (14) | 30.69 | Neutral |
| TRIX (15) | 0.44 | Buy |
| Awesome (5,34) | 0.18 | Buy |
| Ultimate (7,14,28) | 40.90 | Neutral |
| Momentum (10) | 0.19 | Buy |
| Aroon Osc (25) | 12.00 | Buy |
| Hull MA (9) | 6.65 | Buy |
| ADX (14) | 8.93 | Neutral |
| ATR (14) | 0.31 | Info |
The near-term technical picture is bullish. RSI(14) is 50, with the 50-day simple moving average at $6.20 and the 200-day simple moving average at $6.45. The stock is trading within a 30-day range of $4.60 to $9.75, offering near-term liquidity but with notable swings.
Support is identified at $5.80 and resistance at $8.09, providing clear thresholds for traders to monitor while volatility runs at an annualized 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.92 | $6.69 | $11.93 | 0% | Neutral | |
| $8.59 | $11.94 | $17.96 | +79% | Bullish | |
| $8.92 | $13.15 | $21.02 | +97% | Bullish | |
| $8.11 | $12.59 | $21.09 | +88% | Bullish | |
| $8.98 | $14.61 | $25.46 | +118% | Bullish | |
| $7.99 | $13.59 | $24.50 | +103% | Bullish | |
| $8.67 | $15.36 | $28.56 | +130% | Bullish | |
| $13.57 | $25.04 | $47.83 | +274% | Bullish | |
| $13.18 | $25.30 | $49.54 | +278% | Bullish | |
| $12.03 | $24.00 | $48.06 | +259% | Bullish | |
| $17.64 | $39.20 | $86.22 | +486% | Bullish | |
| $27.56 | $61.25 | $140.88 | +816% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.92 | $6.69 | $7.99 | +0.00% |
| June 2026 | $5.94 | $7.12 | $8.85 | +6.45% |
| July 2026 | $5.74 | $7.00 | $8.92 | -1.70% |
| August 2026 | $5.59 | $6.91 | $8.98 | -1.25% |
| September 2026 | $6.15 | $7.68 | $10.14 | +11.17% |
| October 2026 | $6.66 | $8.41 | $11.25 | +9.37% |
| November 2026 | $6.59 | $8.39 | $11.37 | -0.15% |
| December 2026 | $6.78 | $8.71 | $11.93 | +3.77% |
Click any year to see its month-by-month CLNN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, CLNN could reach as high as $11.93, with a base case around $6.69 and support toward $3.92 — roughly 0% from $6.69. Price action looks broadly range-bound.
Expect CLNN to range from $8.59 to $17.96 through 2027. The $11.94 average target implies a +79% move from current prices. That is up +79% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The CLNN price prediction for 2028 points to an average of $13.15 (low $8.92, high $21.02) — a potential gain of +97% on today's $6.69. Momentum favours further upside here.
In 2029, CLNN is projected to trade between $8.11 and $21.09, averaging $12.59 — a potential gain of +88% from today's $6.69. That is -4% versus the projected 2028 average. Buyers look set to stay in control over this stretch.
Clene Inc.'s 2030 outlook centres on $14.61, within a $8.98 to $25.46 range. That is up +16% on the projected 2029 average. That marks a +118% change versus current levels. Momentum favours further upside here.
By 2031, CLNN could reach as high as $24.50, with a base case around $13.59 and support toward $7.99 — roughly +103% from $6.69. Buyers look set to stay in control over this stretch.
Expect CLNN to range from $8.67 to $28.56 through 2032. The $15.36 average target implies a +130% move from current prices. That is up +13% on the projected 2031 average. Momentum favours further upside here.
The CLNN price prediction for 2033 points to an average of $25.04 (low $13.57, high $47.83) — a potential gain of +274% on today's $6.69. Buyers look set to stay in control over this stretch.
In 2034, CLNN is projected to trade between $13.18 and $49.54, averaging $25.30 — a potential gain of +278% from today's $6.69. That is up +1% on the projected 2033 average. Momentum favours further upside here.
Clene Inc.'s 2035 outlook centres on $24.00, within a $12.03 to $48.06 range. That is -5% versus the projected 2034 average. That marks a +259% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, CLNN could reach as high as $86.22, with a base case around $39.20 and support toward $17.64 — roughly +486% from $6.69. Momentum favours further upside here.
Expect CLNN to range from $27.56 to $140.88 through 2050. The $61.25 average target implies a +816% move from current prices. That is up +56% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CLNN today (≈ 149.476831 CLNN) could be worth
$9,155.46
+$8,155.46 (+816%) by 2050 · US Dollar
Based on the average projected CLNN price of $61.25 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CLNNwould be worth at today's price.
$1,000 invested in CLNN on May 27, 2025 (≈ 381.679406 CLNN) would be worth
$2,553.44
+$1,553.44 (+155.3%) today · 2.55× · US Dollar
Based on a CLNN entry price of $2.62 vs. today's $6.69.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.9 | $969.57 | -3.0% |
| 1 month ago | $6.06 | $1,103.96 | +10.4% |
| 3 months ago | $5.36 | $1,248.13 | +24.8% |
| 6 months ago | $10.36 | $645.75 | -35.4% |
| 1 year ago | $2.62 | $2,553.44 | +155.3% |
| All time (5.0y) ago | $215.6 | $31.03 | -96.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CLNN forecast.
Our base-case forecast reaches $13.00 around 2028.
Implied market cap at $13.00: $166.12M
The multi-year forecast shows meaningful upside, with the 2030 average price projected at $14.72 and a projected ROI of 119.7% (bullish). The 2040 forecast envisions an average of $39.38 with a 487.8% ROI (bullish), and by 2050 the average target rises to $62.00 with an 825.4% ROI (bullish). These figures imply substantial long-run upside if CNM-Au8 and related pipeline assets progress through development and commercialization.
Drivers and risks are tied to the inherent path of clinical development and regulatory outcomes, as the asset portfolio includes CNM-Au8 and other CNM products, along with dietary supplements; outcomes are estimates and not guaranteed.
Tap a question to reveal the answer.
The forecast shows an average price of $14.72 in 2030 with a high around $25.67 and an ROI of 119.7%, with bullish sentiment.
For 2026, the forecast shows an average price of $6.70 with a neutral sentiment and an ROI of 0%, indicating no expected gain at that year’s base. Longer term, 2030-2050 show bullish upside.
Yes. The forecast projects an average price of $62.00 in 2050 with an ROI of 825.4%, and a bullish sentiment.
The sentiment is bullish, RSI(14) is 50, SMA50 is $6.20, SMA200 is $6.45. The 30-day range spans from $4.60 to $9.75, with support at $5.80 and resistance at $8.09.
Current price is $6.70 and market cap is $85.61M.
Clene Inc. Community Discussion
0Share your Clene Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.